Previous Close | 1.5400 |
Open | 1.5900 |
Bid | 1.6200 x 1300 |
Ask | 1.6600 x 700 |
Day's Range | 1.5100 - 1.7700 |
52 Week Range | 0.9200 - 3.7900 |
Volume | |
Avg. Volume | 4,533,014 |
Market Cap | 406.291M |
Beta (5Y Monthly) | 1.27 |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Lexicon (LXRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
New post hoc analysis of data from Lexicon's (LXRX) phase III study shows improvements in glycemic control when treated with sotagliflozin for type 1 diabetes and chronic kidney disease.
Lexicon (LXRX) delivered earnings and revenue surprises of 13.04% and 3.24%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?